TrialPath

Find a study

Browse recruiting studies near you — free to check, always your choice.

Match me to a study

90 studies

Recruiting now, in plain language. Every study is watched over by an independent ethics board.

81 studies on the map

A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease — Research Site, BirminghamA Study to Learn About Study Medicine Called PF-08049820 in People With Eczema — Northridge Clinical Trials, NorthridgeEvaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis — National Institutes of Health Clinical Center, BethesdaCardamom and Topical Roseomonas in Atopic Dermatitis — National Institutes of Health Clinical Center, BethesdaDynamic Treatment Regiments for Glucocorticoid Tapering — VA Ann Arbor Healthcare System, Ann Arbor, MI, Ann ArborTo Evaluate the Effect of EXPD-101/FXS7553 Compared With Placebo in Patients With COPD Over 52 Weeks of Treatment — DM Clinical Research - Phoenix, PhoenixA Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis — Investigational Site, Fountain ValleyA Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Atopic Dermatitis (AD) — First OC Dermatology, IrvineA Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1) — University of Colorado Anschutz Medical Campus, AuroraA Study Evaluating BFB759 in Moderate to Severe Atopic Dermatitis — Mountain West Derm - Blackhart PLLC dba Skin Cancer and Dermatology Institute, PhoenixAlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases. — Artiva Investigational Site Tuscaloosa, TuscaloosaA Study to Assess the Safety and Efficacy of Different Doses of ELV001 to Treat Active Rheumatoid Arthritis in Patients With an Inadequate Response to Methotrexate and Tumor Necrosis Factor Inhibition (START SYNERGY) — Arizona Arthritis & Rheumatology Associates, GilbertImproving Coronary Vascular Health in Women — Massachusetts General Hospital, BostonA Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis — Inmagene Site 1, LancasterStudy to Evaluate Soquelitinib in Participants With Moderate to Severe AD — Corvus Clinical Trials, South San FranciscoPh 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234 — Clinical Site 101, Fair LawnA Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2) — Nkarta Investigational Site, OrangeBreathe Easier With Tadalafil Therapy for Dyspnea in COPD-PH — Rocky Mountain Regional VA Medical Center, Aurora, CO, AuroraTreatment of Atopic Dermatitis and Alopecia Areata With Abrocitinib in Individuals With Down Syndrome — Icahn School of Medicine at Mount Sinai, New YorkStudy of Single Doses of SBT777101 in Subjects With Rheumatoid Arthritis — Mayo Clinic, ScottsdaleA Long Term Extension Study to Evaluate the Safety and Efficacy of Afimkibart (RO7790121) in Participants With Atopic Dermatitis — Hamilton Research, LLC, AlpharettaStudy of GS-0151 in Participants With Rheumatoid Arthritis — Pinnacle Research Group, LLC, AnnistonRademikibart Add-on Treatment of an Acute COPD Exacerbation (Seabreeze STAT COPD) — University of Alabama at Birmingham Lung Health Center, BirminghamA Study of BBT002 in Healthy Volunteers (HVs) and in Adult Patients With Chronic Obstructive Pulmonary Disease (COPD) or Chronic Rhiosininusitis With Nasal Polyps (CRSwNP) — Equity Medical Bowling Green, Bowling GreenImaging of Lymphatic Vessels in People With Rheumatoid Arthritis (RA) — University of Rochester, RochesterThe Impact of Botox on Neuroimmune Interactions in Atopic Dermatitis — University of Pittsburgh Medical Center, PittsburghA Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis — Sun Valley Arthritis Center /ID# 278331, PeoriaA Study of LY4213663 in Healthy Participants and Participants With Rheumatoid Arthritis — Pinnacle Research Group, LLC, AnnistonSafety and Pharmacokinetics of LPX-TI641 in Atopic Dermatitis and Psoriasis — Red River Research Partners, FargoThe Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus (SLE) - IFN-CVD — National Institutes of Health Clinical Center, BethesdaA Study of AZD0120 in Autoimmune Diseases — Research Site, TucsonPrevention of Progression of Prediabetes, Obesity and CV Risk — University of Texas Health Science Center at San Antonio, San AntonioFIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients — Anaheim Clinical Trials, LLC, AnaheimA Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD — SEC Clinical Research, LLC, DothanA 3-part Study of SYX-5219 in Healthy Volunteers and Participants With Atopic Dermatitis — Sitryx Clinical Site, Arkansas CityA Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease — University of Alabama at Birmingham Lung Health Center, BirminghamA Study to Test the Safety and Effects of Inhaled GDC-6988 in Participants With Muco-obstructive Disease — University of Alabama at Birmingham, BirminghamFeasibility of Semaglutide in Advanced Lung Disease — University of Pennsylvania Perelman School of Medicine, PhiladelphiaA Study to Evaluate Solrikitug in Participants With COPD (ZION) — University of Alabama at Birmingham Hospital, BirminghamTargeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2) — University of California, San Diego: Dermatology Clinical Trials Unit, San DiegoA Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis — AllerVie Clinical Research, BirminghamA Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab — Physioseq, LLC /ID# 267266, SacramentoA Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions and Subcutaneous Injections of ABBV-519 in Adult Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA) — Pinnacle Research Group /ID# 278677, AnnistonAn Extension Study to Assess Long-Term Safety and Efficacy of Afimkibart in Participants With Rheumatoid Arthritis — DM Clinical Research, TomballEvaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis — First OC Dermatology, Fountain ValleyA Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors) — SunValley Arthritis Center Ltd., PeoriaA Double-Blind, Randomized, Vehicle-Controlled Phase 2 Study to Assess the Efficacy and Safety of GX-03 in Adult Subjects With Moderate to Severe Atopic Dermatitis (Eczema) — ALS Global, IrvingA Study of WIN378 in Participants With Moderate to Severe COPD (Sirius) — WB Contracted Clinical Research Site, Miami LakesA Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases — HonorHealth Research and Innovation Institute, ScottsdaleA Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BGE-102 in Participants With Obesity and Cardiovascular Risk Factors — Site 108, ChandlerOpen-label Single-Center Study to Evaluate the Safety and Efficacy of Combining Rituximab and AB-101 in B-cell Associated Autoimmune Diseases. — IRIS Research and Development, LLC, PlantationStudy Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants — Research Site, BirminghamMechanisms of Semaglutide Therapy in Heart Failure Patients — Greenstone Biosciences, Palo AltoA Dose Response Study to Evaluate the Efficacy and Safety of Oral AP1189 Administered in Disease-Modifying Anti-Rheumatic Drug (DMARD) naïve Participants Participants With Early Rheumatoid Arthritis — Nouvelle Clinical Research LLC, Cutler BayThe Cardiovascular Consequences of Sleep Apnea Plus COPD (Overlap Syndrome) — UCSD Sleep Research, La JollaCombined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD) — Nephrology of North Alabama, DecaturA Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis — Research Site, GlendaleMAD Study of IA-14069 — ICON plc., LenexaA Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis — Atd002 52021, OceansideStudy of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis — Enveda Investigative Site, BirminghamA Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis — Allervie Clinical Research, BirminghamEffects of Treatments on Atopic Dermatitis — National Institutes of Health Clinical Center, BethesdaReduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT — UPMC Children's Hospital of Pittsburgh, PittsburghMetabolic Effects of Angiotensin-(1-7) — Vanderbilt University Medical Center, Nashville: Vascular Function in Health and Disease — George E Wahlen VA Medical Center, Salt Lake CityHyper Polarized Xenon-129 MRI vs Xenon-133 Scintigraphy — University of Virginia Health System, CharlottesvilleLung and Bone Marrow Transplantation for Lung and Bone Marrow Failure — UPMC Presbyterian, PittsburghTesting an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO — University of Alabama at Birmingham Cancer Center, BirminghamErtugliflozin in Chronic Heart Failure — Yale School of Medicine, New HavenHyperpolarized 129Xe MR Imaging of Lung Function in Healthy Volunteers and Subjects With Pulmonary Disease — University of Kansas Medical Center, Kansas CitySympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study) — University of Kansas Medical Center, Kansas CityPulmonary Hypertension SOLAR — Duke University Medical Center, DurhamPRECISION-BP: Precision Chronopharamacotherapy Targeting NP-RAAS-BP Rhythm Axis — University of Alabama at Birmingham, BirminghamEffect of Ensifentrine on Sputum Markers of Inflammation in COPD — University of Alabama at Birmingham, BirminghamEffect of Dapagliflozin on Metabolomics and Cardiac Mechanics in Chronic Kidney Disease — Northwestern University, ChicagoA Study to Investigate the Safety, Tolerability, and Efficacy of BxC-I17e Single and Multiple Dose SC Injection in Patients With Moderate to Severe Atopic Dermatitis — Arkansas Research Trials, North Little RockEffects of Tirzepatide on Muscle and Vascular Health in Obese Older Adults — University of Texas Health Science Center at San Antonio, San AntonioA Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis. — Research Site, AnnistonPlatform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis — Novartis Investigative Site, BirminghamInhaled Treprostinil (Tyvaso Nebulizer) For COPD Patients With Hypoxemia — Duke Asthma Allergy and Airway Center, DurhamClinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD — University of Alabama, Birmingham